Literature DB >> 23695074

Outcome of patients with chronic migraine with medication overuse and depression after duloxetine: influence of coexisting obsessive compulsive disorder.

Marcella Curone1, V Tullo, M Savino, A Proietti-Cecchini, G Bussone, D D'Amico.   

Abstract

Patients with chronic migraine (CM) and medication overuse (MO) have high frequency of psychiatric comorbidity. Aims of this open label, prospective, independent study were: to evaluate the efficacy of duloxetine in a sample of patients with MO due to CM and with concomitant depression; to investigate, if the presence of OCD influences the outcome in this subgroup of patients. A total of 50 consecutive patients (40 F,10 M, aged 20-65 years, mean 39.4 years) from those attending our Headache Center to undergo an inpatient withdrawal programme followed by anti-migraine prophylaxis was enrolled. After a 1-month baseline period, all patients were prescribed duloxetine 30 mg in the morning for the first week, and 60 mg for the following 12 weeks. They filled a daily headache diary during the whole study period. They also completed Hamilton depression rating scale (HDRS) and migraine disability assessment scale (MIDAS) at baseline and at the 12-week follow-up. The primary outcome measure was the percentage of responders, i.e. of patients with a reduction ≥50 % in headache frequency as well as in symptomatic drug consumption. Comparison between patients with and without OCD was performed. Our results showed a rather high responder rate in the total sample (64 %), while none of the patients with OCD fell among responders. MIDAS and HDRS scores had a more evident decrease in patients without OSD. These findings suggest that duloxetine may be effective in patients with MO due to CM and with comorbid depression. They also confirm the importance of a systematic assessment of the psychopathological profile in these patients, and indicate that clinicians should be aware of the relevant prognostic role of OCD in favoring a poor outcome and persistent disability in headache patients with MO.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23695074     DOI: 10.1007/s10072-013-1376-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  15 in total

1.  Obsessive-compulsive aspects as predictors of poor response to treatments in patients with chronic migraine and medication overuse.

Authors:  M Curone; D D'Amico; G Bussone
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

2.  New appendix criteria open for a broader concept of chronic migraine.

Authors:  J Olesen; M-G Bousser; H-C Diener; D Dodick; M First; P J Goadsby; H Göbel; M J A Lainez; J W Lance; R B Lipton; G Nappi; F Sakai; J Schoenen; S D Silberstein; T J Steiner
Journal:  Cephalalgia       Date:  2006-06       Impact factor: 6.292

Review 3.  Intrusive thoughts, obsessions, and appraisals in obsessive-compulsive disorder: a critical review.

Authors:  Dominic Julien; Kieron P O'Connor; Frederick Aardema
Journal:  Clin Psychol Rev       Date:  2007-01-22

Review 4.  Duloxetine: a review of its use in the management of major depressive disorder in older adults.

Authors:  Sohita Dhillon
Journal:  Drugs Aging       Date:  2013-01       Impact factor: 3.923

5.  Psychiatric comorbidity in migraine: a review.

Authors:  F Radat; J Swendsen
Journal:  Cephalalgia       Date:  2005-03       Impact factor: 6.292

6.  Psychopathological profile of patients with chronic migraine and medication overuse: study and findings in 50 cases.

Authors:  M Curone; V Tullo; E Mea; A Proietti-Cecchini; C Peccarisi; G Bussone
Journal:  Neurol Sci       Date:  2011-05       Impact factor: 3.307

7.  Polytherapy for the prophylaxis of chronic migraine: an Italian survey.

Authors:  D D'Amico; M Curone; V Tullo; A Proietti Cecchini; E Mea; G Bussone
Journal:  Neurol Sci       Date:  2011-05       Impact factor: 3.307

8.  Obsessive compulsive disorder and migraine: case report, diagnosis and therapeutic approach.

Authors:  Luiz Paulo Bastos Vasconcelos; Melissa Costa Silva; Esther Angélica Coelho Costa; Ariovaldo Alberto da Silva Júnior; Rodrigo Santiago Gómez; Antônio Lúcio Teixeira
Journal:  J Headache Pain       Date:  2008-09-19       Impact factor: 7.277

9.  Psychiatric comorbidities of chronic migraine in community and tertiary care clinic samples.

Authors:  Antonio Lucio Teixeira; Esther Angélica Coelho Costa; Ariovaldo Alberto da Silva; Igor Alvarenga Moreira dos Santos; Rodrigo Santiago Gómez; Arthur Kummer; Edward C Lauterbach
Journal:  J Headache Pain       Date:  2012-09-01       Impact factor: 7.277

Review 10.  Antidepressants in the treatment of migraine headache.

Authors:  Nestor C Punay; James R Couch
Journal:  Curr Pain Headache Rep       Date:  2003-02
View more
  4 in total

Review 1.  Medication overuse headache.

Authors:  Valerie Cheung; Farnaz Amoozegar; Esma Dilli
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

Review 2.  Migraine With Comorbid Depression: Pathogenesis, Clinical Implications, and Treatment.

Authors:  Nailah Asif; Apurva Patel; Deepanjali Vedantam; Devyani S Poman; Lakshya Motwani
Journal:  Cureus       Date:  2022-06-16

3.  Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study.

Authors:  Richard B Lipton; Joshua M Cohen; Maja Galic; Michael J Seminerio; Paul P Yeung; Ernesto Aycardi; Marcelo E Bigal; Kristen Bibeau; Dawn C Buse
Journal:  Headache       Date:  2021-04       Impact factor: 5.887

4.  Health and quality of life in patients with medication overuse headache syndrome after standardized inpatient rehabilitation: A cross-sectional pilot study.

Authors:  Thomas Benz; Achim Nüssle; Susanne Lehmann; Andreas R Gantenbein; Peter S Sándor; Achim Elfering; André G Aeschlimann; Felix Angst
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.